CERA Detection and Stability in Blood Versus Urine
Drug Testing and Analysis · 2026
DOI: 10.1002/dta.3960 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Drug Testing and Analysis, 2026. Verfasst von Olivier Salamin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausan…. Hauptthemen laut MEDLINE: Substance Abuse Detection, Erythropoietin, Polyethylene Glycols, Ethanolamines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Erythropoietin receptor agonists (ERAs), including continuous erythropoietin receptor activators (CERAs), are potent blood doping substances used to enhance endurance performance by stimulating erythropoiesis. While traditionally detected through direct analysis of urine or serum samples using sarcosyl‐polyacrylamide gel electrophoresis (SAR‐PAGE) and western blotting, the slow urinary elimination of third‐generation ERAs like CERA has shifted anti‐doping strategies toward serum‐based detection. This study compared the detectability and stability of CERA in urine and serum matrices and evaluated the added value of combining direct detection with hematological profiling. Using samples from a controlled CERA administration study and an authentic case example, we assessed CERA detection in serum, urine, and simulated dried blood spot (DBS) matrices (Tasso‐M20). Additionally, we conducted stability experiments by incubating spiked matrices at 37°C for up to 72 h. Our results confirmed the superior stability and consistent detectability of CERA in serum and DBS compared with urine. Moreover, hematological alterations such as increased reticulocytes percentage flagged by the Athlete Biological Passport (ABP) supported targeted serum testing, leading to the successful detection of CERA. These findings highlight the importance of systematic blood collection for both direct and indirect detection strategies. Furthermore, DBS samples showed promising analytical performance and resistance to elevated temperature, suggesting their utility as minimally invasive alternatives in anti‐doping programs. Overall, our study reinforces the relevance of blood matrices in the detection of CERA and advocates for the broader integration of blood‐based strategies in targeting doping practices with ERAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Nordic Athlete Passport Management Unit, Norwegian Doping Control Laboratory, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Olivier Salamin
Zitieren
APA
Salamin, O., Chappuis, J., Bækken, L. V., Kuuranne, T., & Leuenberger, N. (2026). CERA Detection and Stability in Blood Versus Urine. Drug Testing and Analysis. https://doi.org/10.1002/dta.3960
Vancouver
Salamin O, Chappuis J, Bækken LV, Kuuranne T, Leuenberger N. CERA Detection and Stability in Blood Versus Urine. Drug Testing and Analysis. 2026. doi:10.1002/dta.3960
BibTeX
@article{Salamin2026,
author = {Salamin, Olivier and Chappuis, Joséphine and Bækken, Lasse V and Kuuranne, Tiia and Leuenberger, Nicolas},
title = {CERA Detection and Stability in Blood Versus Urine},
journal = {Drug Testing and Analysis},
year = {2026},
doi = {10.1002/dta.3960}
}
EUVIMED